Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 80 points (-0.5%) at 17,033 as of Monday, Sept. 29, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 959 issues advancing vs. 2,053 declining with 145 unchanged. The Drugs industry currently sits up 0.4% versus the S&P 500, which is down 0.5%. A company within the industry that increased today was Bristol-Myers Squibb Company ( BMY), up 1.1%. On the negative front, top decliners within the industry include Seattle Genetics ( SGEN), down 6.1%, Perrigo ( PRGO), down 1.3%, AbbVie ( ABBV), down 1.2%, Regeneron Pharmaceuticals ( REGN), down 1.1% and Sanofi ( SNY), down 1.0%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $0.29 (0.6%) to $48.41 on heavy volume. Thus far, 918,701 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 964,200 shares. The stock has ranged in price between $47.94-$48.58 after having opened the day at $48.01 as compared to the previous trading day's close of $48.12. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $131.4 billion and is part of the health care sector. Shares are up 30.2% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Novo Nordisk A/S Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.